CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Alto Neuroscience, Inc.

ANRO
$1.10BSmall Cap

Next catalyst

Phase 2December 2026

ALTO-300

Major Depressive Disorder

Get an email about ANRO's next catalysts

Track Alto Neuroscience (ANRO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline

Catalyst Timeline

3 upcoming, 2 past

Phase 2Next

ALTO-300 Phase 2 Est. Readout

December 2026~ALTO-300325

Estimated primary completion for ALTO-300 trial (NCT05922878) in Major Depressive Disorder. Topline data typically follows completion by weeks to months.

Source
Phase 2

ALTO-100 Phase 2 Est. Readout

September 2027~ALTO-100200

Estimated primary completion for ALTO-100 trial (NCT06656416) in Bipolar Disorder I or II With a Major Depressive Episode. Topline data typically follows completion by weeks to months.

Source
Phase 2

ALTO-207 Phase 2 Est. Readout

November 2027~ALTO-207178

Primary completion for ALTO-207 trial (NCT07553637) in Treatment-resistant Depression (TRD)

Source

How ANRO's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaMOUNTAIN VIEW

Frequently asked questions

What is in Alto Neuroscience, Inc.'s drug pipeline?→

CatalystAlert tracks 13 drug candidates in Alto Neuroscience, Inc.'s (ANRO) pipeline across Phase 3, Phase 2. Its lead program is XKH004 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Alto Neuroscience, Inc.'s next FDA catalyst?→

Alto Neuroscience, Inc.'s (ANRO) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track ANRO biotech catalysts?→

Add ANRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alto Neuroscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply